Crizotinib could be used in first or second line of treatment of advanced NSCLC patients with ALK gene rearrangement; however, second generation of ALK-TKIs (ceritinib, alectinib) could be used in patients with crizotinib resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.